Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 16, 2017

Primary Completion Date

March 8, 2018

Study Completion Date

March 8, 2018

Conditions

Growth Hormone DisorderAdult Growth Hormone DeficiencyGrowth Hormone Deficiency in Children

Interventions

DRUG

Somapacitan

3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg

Trial Locations (1)

Novo Nordisk Investigational Site, Bratislava